iShares MSCI Indonesia ETF vs Koninklijke Philips NV — how do they compare? iShares MSCI Indonesia ETF trades at $12.41 (market cap $410.85M), while Koninklijke Philips NV trades at $24.38 (market cap $23.68B). The key difference: Koninklijke Philips NV is far larger — about 57.6× iShares MSCI Indonesia ETF's market cap, and Koninklijke Philips NV pays a 4.21% dividend while iShares MSCI Indonesia ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Indonesia ETF for 75 Days and Koninklijke Philips NV for 84 Days on average.
| EIDO | PHG | |
|---|---|---|
Market Cap | $410.85M | $23.68B |
Volume | 726,664 | 1,443,075 |
52-Week High | $19.22 | $32.91 |
52-Week Low | $10.80 | $23.81 |
Typical Hold Time | 75 Days | 84 Days |
Sector | — | Health |
Enterprise Value | — | $30.07B |
Dividend Yield | — | 4.21% |
Signals from Pluang's Aura AI — not financial advice
EIDO (iShares MSCI Indonesia ETF) trades at $11.86, down 0.59% with bearish technical signals from moving averages. The ETF shows neutral oscillator readings but faces weak price action despite potential valuation appeal. Recent news highlights foreign capital rotation away from Asian equities and Indonesia's limited benefit from commodity gains.
Outlook remains cautious due to technical downtrend and sector concentration risks. The 44% financials weighting and modest EPS growth constrain upside, though seasonal patterns may offer temporary support. Key risks include regional market volatility and dependence on commodity cycles.
PHG trades at $24.09, down 0.25% on the day, with a bearish technical signal despite recent earnings beats. The company shows improving fundamentals with net income turning positive to $895M in 2025 after previous losses, supported by strong operational cash flow of $1.17B. Recent news highlights product innovations including new CT systems and AI healthcare tools, while institutional investors like Bank of America and Arrowstreet Capital have increased positions.
PHG presents a mixed outlook with solid profitability recovery but technical weakness. The stock offers value at reasonable valuations (P/E 18.84, P/S 1.18) and analyst consensus leans Hold (63.64%). Key risks include cybersecurity threats (Reuters, 2026-08-13) and debt levels, while opportunities lie in healthcare technology expansion and Exor's potential increased stake to 22% (Reuters, 2026-08-11).
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
The fund generally will invest at least 80% of its assets in the component securities of the underlying index and in investments that have economic characteristics that are substantially identical to the component securities of the underlying index. The index is a free float-adjusted market capitalization-weighted index that is designed to measure the performance of the large-, mid- and small-capitalization segments of the equity market in Indonesia. The fund is non-diversified.
Read more on EIDO →Philips is a diversified global healthcare company operating in three segments: diagnosis and treatment, connected care, and personal health. About 50% of the company's revenue comes from the diagnosis and treatment segment, which features imaging systems, ultrasound equipment, image-guided therapy solutions and healthcare informatics. The connected care segment (27% of revenue) encompasses monitoring and analytics systems for hospitals and sleep and respiratory care devices, whereas the personal health business (remainder of revenue) includes electric toothbrushes and men's grooming and personal-care products. In 2021, Philips generated EUR 17.2 billion in sales and had 80,000 employees in over 100 countries.
Read more on PHG →